USIL Therapeutics | Pioneering the future of nuclear defense

Our Mission

Protecting Lives Against Radiation Threats

USIL Therapeutics pioneers breakthrough medical solutions to safeguard people from the dangers of ionizing radiation. Our mission is to transform radiation defense with treatments and potential cures that go beyond symptomatic care, delivering true whole-body protection. Partnering with governments, defense, and energy sectors worldwide, we provide scalable, effective countermeasures that strengthen resilience and global preparedness in the face of nuclear and radiological risks.

Global Radiation Protection

We are pioneering next-generation medical countermeasures to safeguard populations, critical infrastructure, and strategic sectors from the threats of ionizing radiation.

€10M+ Assets

Our asset base is anchored by a portfolio of patented molecules designed to become the world’s first-in-class radioprotectors by 2031. Backed by decades of validated research and clinical models, these patents combine scientific excellence with strong commercial potential.

Global Reach

We collaborate with governments, defense agencies, and healthcare systems across continents. By combining advanced science with international partnerships, we ensure radiation protection is scalable, deployable, and resilient in civilian and defense settings.

10+ Experts

Our team brings over 25 years of expertise in radiobiology, pharmaceuticals, defense, and large-scale manufacturing. Backed by leading scientists and regulatory specialists, we deliver the innovation and execution to bring countermeasures to market.

Products in Development

We are advancing two breakthrough formulations, UT-241 and UT-242, currently in development to deliver next-generation protection against ionizing radiation.

UT-241: Auto-Injector (Syringe Device)

RAPID-RESPONSE RADIATION COUNTERMEASURE

UT-241 is an easy-to-use, ready-to-deploy injectable designed for rapid intervention in critical field situations — from nuclear accidents to battlefront emergencies. It provides immediate, whole-body protection against ionizing radiation. Portable, stable, and simple to administer, UT-241 ensures reliable defense for military, energy, and first-responder operations where speed and simplicity are vital.

UT-242: IV Infusion (Vial Formulation)

EXTENDED WHOLE-BODY RADIOPROTECION

UT-242 is an intravenous infusion therapy designed for comprehensive, long-lasting protection against ionizing radiation. Intended for hospitals, field clinics, and specialized defense settings, it safeguards all major organ systems during high-risk exposure events. Scalable and adaptable, UT-242 strengthens resilience for both civilian and military operations where extended care is essential.

Advancing Full-Body Radioprotection Beyond Earth

USIL Therapeutics has been selected by the European Space Agency (ESA) for an in-orbit validation mission on the International Space Station (ISS), conducted in partnership with Yuri GmbH. The study will test our full-body radioprotection and mitigation compound under microgravity and intense cosmic radiation, replicating some of the harshest conditions known to science to validate its stability and efficacy in space.

Funded by ESA, this project represents a breakthrough in dual-use biotechnology: bridging defense, healthcare, and space exploration. Insights from orbit will accelerate our path toward field-ready biological protection for soldiers, first responders, astronauts, and future space travelers, reinforcing resilience for both terrestrial crises and future space missions.

Core Team & Advisory Board

Fred Marin

CEO & CO-FOUNDER

Pharm.D. by training, entrepreneur with 20+ years’ experience leading multifunctional, multicultural teams in diverse industries.

Bruno Le Grand

CSO & CO-FOUNDER

PhD, pharmacology and drug development expert with 35 years’ experience in biopharma and healthcare.

Bruno Flamion

CRO & CO-FOUNDER

MD, PhD, former Chair of the Scientific Advice Working Party at the European Medicines Agency (EMA).

Michel Andraud

CFO & CO-FOUNDER

CFO with 30+ years’ experience in finance and M&A across international industrial groups.
‍

Valentin Wiedling

CDO & CO-FOUNDER

Entrepreneur, Harvard-trained, with 15+ years’ experience in investor relations and scaling international ventures.

Catherine Federspiel

HEAD OF STRATEGY

15+ years’ experience in international consulting, aligning strategy and operations to optimize performance.

Jose Morente

HEAD OF MANUFACTURING

International executive with 25+ years’ experience in automotive with focus on manufacturing.

Alain Rodermann

INVESTMENT ADVISOR

VC leader with 27+ years’ experience, founder of Expon Capital, driving deeptech and innovation across Europe.

Stefan Dimitrov-Lübcke

SPACE ADVISOR

Yuri LUX CEO, expert in payloads to Low Earth Orbit with 20+ years in technology regulation and life sciences business development.

Why Partner with USIL Therapeutics?

USIL Therapeutics is addressing one of the world’s most urgent unmet medical needs: protection against ionizing radiation. With patented molecules, validated efficacy, and a regulatory fast-track underway, we are uniquely positioned to become a global leader in radiation countermeasures.

Headquartered in Luxembourg, an EU and NATO hub with direct access to defense supply chains, global logistics, and European space and health programs, we benefit from partnerships with ESA, leading research institutions, and industry leaders. Together with strategic partners and investors, we aim to scale dual-use medical countermeasures and bring life-saving solutions to market at the heart of international security and innovation.

Publications

Hydrogen Sulfide Metabolism and Pulmonary Hypertension

This review highlights the role of hydrogensulfide (H₂S) as a key regulator of vascular remodeling, inflammation, andoxidative stress in pulmonary hypertension (PH). It shows how disrupted H₂Smetabolism affects KATP channel activity and hypoxia responses, identifying H₂S supplementation as a promising antioxidative and vasoprotective therapy. Click here to access this publication.

Inhibition of NF-κB Activation in Human T-Cell Lines by Anetholdithiolthione

This study demonstrates thatanetholdithiolthione (ADT), a pro-glutathione antioxidant, inhibits NF-κBactivation in human T-cells under oxidative and inflammatory stress. ADT reduced lipid peroxidation, boosted glutathione levels, and showed a protective redox-modulating effect, highlighting its potential in HIV and oxidative stress–related disorders. Click here to access this publication.

Targeting Human Lung Adenocarcinoma with a Suppressor of Mitochondrial Superoxide Production

This preclinical study shows that AOL, amitochondrial ROS suppressor (S1QEL), reduces tumor growth in human lung adenocarcinoma by lowering ROS without affecting complex I activity. AOL reprograms cancer metabolism, suppresses the Warburg effect, and modulates NDUFV1, its identified binding site - demonstrating a dual role in REDOX controland cancer signaling. Click here to access this publication.

Effects of OP2113 on Myocardial Infarct Size and No Reflow in a Rat Myocardial Ischemia Reperfusion Model

This study highlights the cardioprotective effects of OP2113, a mitochondrial ROS–modulating compound, in a ratischemia/reperfusion model. OP2113 reduced mtROS generation, preserved ATPlevels, and significantly lowered infarct size and no-reflow area withoutaffecting hemodynamics, supporting its potential as a mitochondrial-targetedtherapy for myocardial injury. Click here to access this publication.

An old medicine as a new drug to prevent mitochondrial complex I from producing oxygen radicals

This study identifies OP2113 as the first approved drug to selectively inhibit mitochondrial ROS production at the IQ site of complex I without affecting oxidative phosphorylation. In ex vivo ratheart models, it protected cardiac tissue and preserved contractile function, highlighting its potential as a mitochondrial ROS blocker (S1QEL) for neurodegenerative and ischemia-reperfusion disorders. Click here to access this publication.